- Musical Chairs In UK Biotech Sector: Last week saw severalsurprise moves among UK biotechnology company executives. David Horrobin, founder of Scotia Holdings, announced he was to leave the company - along with his co-founding wife Sherri Clarkson (who will depart in June 1998), to set up a new business - Scarista Ltd - which will license some of Scotia's technology in the area of asthma and schizophrenia products, in return for a L1 million ($1.65 million) advance, milestone payments of up to L26 million and 5%-12.5% royalties on future sales. Replacing Mr Horrobin (who remains a non-executive director) as chief executive is Robert Dow. Also leaving is Jeffrey Boily, managing director of worldwide commercial operations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze